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Abstract
Introduction: The prediction of therapeutic response to rituximab in rheumatoid arthritis is desirable. We
evaluated whether analysis of B lymphocyte subsets by flow cytometry would be useful to identify non-responders
to rituximab ahead of time.
Methods: Fifty-two patients with active rheumatoid arthritis despite therapy with TNF-inhibitors were included in
the national rituximab registry. DAS28 was determined before and 24 weeks after rituximab application. B cell
subsets were analyzed by high-sensitive flow cytometry before and 2 weeks after rituximab administration.
Complete depletion of B cells was defined as CD19-values below 0.0001 x109 cells/liter.
Results: At 6 months 19 patients had a good (37%), 23 a moderate (44%) and 10 (19%) had no EULAR-response.
The extent of B lymphocyte depletion in peripheral blood did not predict the success of rituximab therapy.
Incomplete depletion was found at almost the same frequency in EULAR responders and non-responders. In
comparison to healthy controls, non-responders had elevated baseline CD95+ pre-switch B cells, whereas
responders had a lower frequency of plasmablasts.
Conclusions: The baseline enumeration of B lymphocyte subsets is still of limited clinical value for the prediction
of response to anti-CD20 therapy. However, differences at the level of CD95+ pre switch B cells or plasmablasts
were noticed with regard to treatment response. The criterion of complete depletion of peripheral B cells after
rituximab administration did not predict the success of this therapy in rheumatoid arthritis.
Introduction
The use of monoclonal antibodies (mAbs) against cyto-
kines or lymphocyte surface molecules has opened new
therapeutic options for patients with rheumatoid arthritis
(RA) [1]. By the prediction of a clinical response, these
drugs, which are expensive and have the potential for ser-
ious toxicity, could be allotted to those patients who
would benefit most [2]. B-cell monitoring has been
extensively used recently to assess the effect of B cell-
directed therapies and the reconstitution of the periph-
eral blood B-cell repertoire after treatment with the B
cell-depleting mAb rituximab. Initially, the clinical
response to this therapy was thought not to be correlated
to B-cell subset distribution or depletion [3]. This view
has been challenged by using high-sensitivity flow
cytometry, a technique originally developed to detect
small numbers of residual malignant cells. Thus, com-
plete depletion of B cells 2 weeks after the first infusion
has been suggested to be an indicator for therapy respon-
siveness [4-6]. Furthermore, subsequent articles indicated
that complete depletion is also a prognostic factor for re-
treatment [5] and efficacy of the rituximab therapy [6].
Several articles have analyzed the changes in B-cell sub-
sets following depletion therapy with rituximab [7-9]. In
most articles, B cells were characterized by the surface mar-
kers IgD, CD27, CD38, and CD24, which allow separation
of newly generated ‘transitional’ (IgD+, CD27-, CD24hi, and
CD38hi) [10], naïve (IgD+ and CD27-), pre-switch (IgD+
and CD27+) and post-switch (IgD- and CD27+) memory,
and double-negative B (IgD- and CD27-) cells and plasma-
blasts (IgD- and CD27++) [11-13] in the peripheral blood.
We set out to further delineate B-cell subsets by using
high-sensitivity flow cytometry that might help to char-
acterize RA patients who would benefit from rituximab
therapy. We expanded our analysis to the co-stimulatory
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marker CD80, which had been shown to be a potent
regulator of IgG secretion by previously activated B cells
[14], and CD95, which had been correlated with disease
activity in systemic lupus erythematosus (SLE) [13].
Materials and methods
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Patients and controls
Fifty-two patients undergoing de novo treatment with ritux-
imab for active RA were included in the national ‘B Cell
surveillance’ registry. The participating clinical rheumatolo-
gists from local and remote hospitals judged the need for
the routine administration of rituximab. Informed consent
was obtained from all patients before entering the study, in
accordance with the protocol approved by the local ethics
committee of the Medical University of Graz. All patients
received two 1,000 mg infusions of rituximab preceded by
the administration of 100 mg of prednisolone [15]. The
characteristics of all patients are shown in Table 1. Disease
activity score using 28 joint counts (DAS28) using the ery-
throcyte sedimentation rate was determined before and 2
and 24 weeks after rituximab application in order to deter-
mine the European League Against Rheumatism (EULAR)
response. Peripheral blood samples from 17 healthy donors
(15 females and two males; mean age of 64 years) were
used to determine the normal range for the different B-cell
subsets.
Lymphocyte phenotyping
Peripheral blood samples were drawn before and 15 days
after the first rituximab infusion. Peripheral mononuclear
cells were prepared as described [4] and stained with the
following antibodies: fluorescein isothiocyanate-labeled
IgD, phycoerythrin (PE)-conjugated CD24, allophycocya-
nin (APC)-conjugated CD27, PE-Cy7-labeled CD38, APC-
H7-conjugated CD45, horizon Blue-labeled CD19, pyri-
dine-chlorophyll-protein (PerCP)-conjugated CD3 and
CD14, and PE-labeled CD80 and CD95 (all mAbs were
obtained from BD Biosciences, Schwechat, Austria). Five
hundred thousand CD45+ cells were acquired and ana-
lyzed by using a seven-channel flow cytometry (BD Canto
II cytometer, Software FACSDiva; BD Biosciences).
According to their surface staining in the CD27/IgD blot,
B cells were classified as naïve (CD19+, IgD+, and CD27-),
pre-switch memory (CD19+, IgD+, and CD27+), post-
switch memory (CD19+, IgD-, and CD27+), and double-
negative (CD19+, IgD-, and CD27-) cells. Plasmablasts
were classified as CD19+, IgD-, and CD27++ [12,16]. In
addition, the intensity of the CD38 expression was deter-
mined in the post-switch memory and plasmablast popu-
lations since this molecule was recently shown not to be
constantly expressed within the populations [16,17]. The
distribution of co-stimulatory molecules and the FAS
Table 1 Baseline characteristics of patients included in this study
Parameter Responders Non-responders P value
(n = 42) (n = 10)
Age in years, mean ± SE 62.7 ± 1.9 60.8 ± 3.1 NSa
Female gender, percentage 81.0 60.0 NSb
Disease duration in years, mean ± SE 11.7 ± 1.3 16.2 ± 3.9 NSa
ESRc, mean ± SE 39.2 ± 3.8 43.3 ± 11.8 NSa
DAS28-ESR, mean ± SE 5.9 ± 0.2 4.9 ± 0.3 0.016a
Lymphocytesd, mean ± SE 2,138 ± 174 3,083 ± 23 0.0279a
RF-positive, percentage 90.8 100.0 NSb
ACPA-positive, percentage 76.9 80.0 NSb
Double-seropositive, percentage 71.8 80.0 NSb
Double-seronegative, percentage 7.7 0.0 NSb
Concomitant MTX usage, percentage 40.4 41.7 NSb
Previous sDMARD, mean ± SE 2.6 ± 0.1 2.0 ± 0.3 NSa
Previous TNF inhibitors, mean ± SE 1.1 ± 0.1 1.4 ± 0.4 NSa
No previous biologics, percentage 24.3 11.1 NSb
One previous biologic, percentage 43.2 55.6 NSb
Two previous biologics, percentage 27.1 11.1 NSb
Three previous biologics, percentage 5.4 22.2 NSb
Systemic steroids, percentage 40.0 31.0 NSb
aP values were calculated by using Mann-Whitney test; bP values were calculated by using the chi-squared test; cmm per 1 hour; dG per liter (normal range is 1.0
to 4.8). ACPA, anti-citrullinated peptide antibody; DAS28, disease activity score using 28 joint counts; ESR, erythrocyte sedimentation rate; MTX, methotrexate; NS,
not significant; RF, rheumatoid factor; sDMARD, synthetic disease-modifying anti-rheumatic drug; SE, standard error; TNF, tumor necrosis factor.
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receptor on the different B-cell subsets was determined by
replacing CD24 with CD80 or CD95. Complete depletion
of B cells was defined as CD19 values of below 0.0001 ×
109 cells per liter. The gating strategy and representative
dot blots can be found in Figure S1 of Additional file 1.
Since 41% of the blood samples coming from peripheral
hospitals had to be transported for more than 12 hours,
we compared 15 samples of patients with RA in a pair-
wise fashion (2 and 24 hours after blood letting)
and found no significant change in absolute counts of
B-lymphocyte subsets after this time.
Statistical analyses
Data were analyzed for normal distribution in order to
decide whether to use parametric or non-parametric
tests. Values are expressed as the mean ± standard error
of the mean or as median (interquartile range) and were
calculated by using GraphPad Prism (version 5.0b;
GraphPad Software, La Jolla, CA, USA). Baseline clinical
variables and B-cell subsets as predictors of response to
the first cycle of rituximab were compared with non-
responders by using univariate logistic regression.
P values of less than 0.05 were considered significant.
Results
Characterization of rheumatoid arthritis patients
Table 1 summarizes the baseline demographics and clini-
cal characteristics of the enrolled patients (n = 52), and
Figure 1 shows the DAS28 values at baseline and 24 weeks
after rituximab application. At baseline, EULAR respon-
ders and non-responders were significantly different with
regard to the DAS28 only. Interestingly, this difference
was due to elevated DAS28 values in RA patients with
moderate EULAR response (6.2 ± 0.2; P ≤ 0.0004),
Figure 1 Disease activity score using 28 joint counts (DAS28) at baseline and 24 weeks after rituximab application in European
League Against Rheumatism (EULAR) responders and non-responders. The lines indicate the border between low disease activity (LDA),
moderate disease activity (MDA), and high disease activity (HDA).
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whereas patients with good response were not statistically
different from EULAR non-responders (5.7 ± 0.3 versus
4.9 ± 0.3, respectively). In our small cohort, the autoanti-
body status had no influence on the effect of the treatment
with rituximab. The few patients with double-seronegative
RA were all in the responder group.
B-cell depletion and clinical response
Two weeks after the first rituximab infusion, there was a
dramatic reduction in the number of B cells in all
patients with RA. When high-sensitivity flow cytometry
was used, the difference in the number of B cells 15
days after rituximab did not reach statistical significance
between responders and non-responders. The median
numbers (interquartile ranges) of B cells per 109/L were
0.022 (0.008 to 0.043) in RA patients with good EULAR
response, 0.022 (0.011 to 0.059) in patients with a mod-
erate response, and 0.008 (0.003 to 0.035) in patients
with no response (Figure 2).
B-cell subpopulations and clinical response
At baseline, the differences in the frequency of naïve,
double-negative, pre-switch memory, and post-switch
memory B cells between EULAR responders and non-
responders did not reach significance. In addition, the
expressions of CD80 or CD95 on the B-cell subsets
were similar between RA patients and healthy controls.
Only a few naïve B cells in patients with RA expressed
the co-stimulation and activation markers (1.8% (1.1% to
3.5%) and 4.9% (3.0% to 8.5%), respectively), whereas the
Figure 2 Number of B cells 15 days after the first rituximab infusion. Each dot represents one patient. The horizontal lines represent the
median.
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highest frequency was found in post-switch memory B
cells (58.0% (42.0% to 94.1%) and 65.8% (55.1% to
79.0%), respectively). In all populations analyzed, there
was a significant correlation between the frequency of
CD95+ and CD80+ B-cell subsets. In responders, this
correlation was highest in the double-negative subset
(R2 = 0.71; P ≤ 0.0001) but was lowest in non-respon-
ders and controls (R2 = 0.520; P ≤ 0.0437 and R2 =
0.384; P ≤ 0.0080, respectively).
When the frequencies of B cells in responders and
non-responders at baseline were compared with those in
healthy controls, significant dissimilarities were seen
(Figure 3). Thus, responders had significantly more dou-
ble-negative B cells (Figure 3a) and fewer plasmablasts
(Figure 3b) in comparison with controls: 6.6% (4.1% to
11.1%) versus 4.4% (2.8% to 6.9%), P ≤ 0.02 and 0.6%
(0.3% to 1.3%) versus 1.3% (0.5% to 2.8%), P ≤ 0.03,
respectively. The frequencies of these B-cell subsets in
non-responders were 6.2% (2.1% to 10.7%) and 0.9%
(0.3% to 2.8%), respectively.
The total cohort of patients with RA had a signifi-
cantly lower frequency of CD38hi B cells within the
Figure 3 B cell phenotype distribution before rituximab. Frequencies of (a) CD27- IgD- double-negative B cells and (b) CD27++ IgD-
plasmablast in patients with rheumatoid arthritis (RA) at baseline and in healthy age-matched controls. The percentages of CD38hi cells within
(c) the post-switch memory B cells and (d) plasmablasts (that is, late plasmablasts [16]) are shown. (e) The frequency of CD95+ cells within the
pre-switch memory B cells is depicted. Significant differences between the populations using Mann-Whitney-test are indicated. Of note, the
difference between non-responders and responders was significant using univariate logistic regression analysis.
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post-switch memory subset (P ≤ 0.0001). Thus, the
median (interquartile range) frequencies of this B-cell
subset were 0.9% (0.3% to 2.1%) in responders, 1.3%
(0.3% to 3.9%) in non-responders, and 18.2% (14.7% to
34.5%) in controls (Figure 3c). Furthermore, the fre-
quency of CD38hi B cells within plasmablasts was signifi-
cantly diminished in EULAR responders compared with
controls: 28.1% (9.6% to 54.3%) versus 61.1% (44.1% to
66.0%), P ≤ 0.001 (Figure 3d). In contrast, only non-respon-
ders had a significantly higher frequency of CD95+ pre-
switch memory B cells than controls: 52.6% (37.9% to
62.6%) versus 37.9% (26.5% to 49.3%), P ≤ 0.023 (Figure 3e).
The frequency of CD95+ cells in the other B-cell subsets is
depicted in Figure S2 of Additional file 2. As indicated in
Figure 3, no significant differences were found between
EULAR responders and non-responders.
Prediction of first-cycle response
When univariate logistic regression analysis was used
(Table 2), only a low frequency of plasmablasts was a
valid predictor for EULAR responsiveness (odds ratio of
2.22; P ≤ 0.04). In our small cohort, complete depletion
on day 15 let us calculate an odds ratio of 2.33 for the
lack of a therapeutic response to rituximab (P = 0.516).
Discussion
In our small registry cohort of patients with routinely
treated RA, complete depletion of B cells 15 days after
the first rituximab infusion was not a prognostic factor
for clinical response. We did not find technical explana-
tions for this discrepancy with previous reports [4-6].
The time lag between blood letting and analysis was
proven not to be a valid explanation since no significant
difference was found between samples that were ana-
lyzed within 6 or 24 hours (Figure S3 of Additional
file 3). We cannot exclude biological differences between
our cohort and the patients in previous reports [4-6].
Interestingly, in the regression analysis, the results for
baseline distribution of B-cell subsets in responders and
non-responders (Table 2) were similar to those reported
by Vital and colleagues [5]. Thus, in both studies, fewer
plasmablasts were significantly associated with response
to rituximab. These B-cell populations were also signifi-
cantly less frequent in responders than in healthy con-
trols (Figure 3b, d).
Analyzing the frequency of the major B-cell subsets (that
is, naïve, pre-switch and post-switch memory, and double-
negative B cells and plasmablasts) in our RA patients
before rituximab treatment, we and others did not find a
significant difference with healthy age-matched controls
[11]. Interestingly, separating the RA population in
EULAR responders and non-responders revealed a signifi-
cantly higher percentage of double-negative (IgD-/CD27-)
B cells in the former group (Figure 3a). In a recent study
in healthy older people, this population of B cells was
shown to be enriched in exhausted cells [18]. In patients
with RA, the humoral immune system already seems to be
overstimulated, driving more B cells into the double-nega-
tive subset in comparison with healthy controls (Figure 3).
The significant result for EULAR responders might be
related primarily to the higher number of patients in this
group. In these patients (in contrast to patients with SLE
[13]), disease activity did not correlate with CD95 expres-
sion on double-negative B cells (data not shown).
In all patients with RA, CD38hi post-switch memory B
cells were significantly reduced in comparison with
Table 2 Baseline clinical variables and B-cell subsets in responders and non-responders, as determined by univariate
logistic regression
Clinical variable or B-cell subset Responders Non-responders OR (95% CI) P value
Age in years, median (interquartile range) 62.9 (58.2-67.7) 60.6 (49.7-71.4) 0.99 (0.92-1.05) 0.647
sDMARD use, median (interquartile range) 2.5 (2.1-2.8) 2.4 (1.5-3.3) 0.84 (0.33-2.14) 0.956
Prior anti-TNF use, median (interquartile range) 1.1 (0.8-1.4) 1.1 (0.3-2.0) 1.02 (0.37-2.80) 0.978
ESRa, median (interquartile range) 6.1 (5.4-6.8) 5.0 (2.9-7.2) 0.74 (0.47-1.17) 0.202
Rheumatoid factor, number (percentage)
Positive 27 (90.0) 7 (100.0) 1.91 (0.43-8.32) 0.389b
Negative 3 (10.0) 0 (0.0)
B-cell subset, median (interquartile range)
Naïve cellsc 8.9 (8.6-9.3) 9.2 (8.6-9.8) 1.51 (0.56-4.11) 0.416
Post-switch memoryc 7.4 (7.1-7.6) 7.9 (7.4-8.5) 3.91 (0.93-16.45) 0.063
Plasmablastsd 3.8 (3.3-4.4) 5.2 (3.8-6.6) 2.22 (1.04-4.74) 0.040
B-cell depletion, number (percentage)
Complete 2 (6.7) 1 (14.3) 2.33 (0.18-30.10) 0.516
Incomplete 28 (93.3) 6 (85.7)
aSquare root values; bcalculated from contingency table, Pearson-Mantel-Haenszel P value; cnatural log (absolute number of cells); dnatural log (absolute number
of cells + 1). anti-TNF, anti-tumor necrosis factor; CI, confidence interval; ESR, erythrocyte sedimentation rate; OR, odds ratio; sDMARD, synthetic disease-
modifying anti-rheumatic drug.
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healthy age-matched controls (Figure 3c). CD38 is a
45-kDa transmembrane glycoprotein expressed on dif-
ferent human cells, including T and B lymphocytes [17].
Activation of naïve B cells leads to an upregulation of
this molecule, and transition of activated B lymphocytes
into memory cells is characterized by loss of CD38
[19,20] but this molecule reappears when B cells develop
into plasmablasts and plasma cells [21]. Plasmablasts
can be separated further into CD38- early plasmablasts
and CD38++ late plasmablasts [16]. Interestingly, in
synovial tissue of patients with RA, CD38- B cells appear
to serve as immunoglobulin-producing effector B cells
[22]. Whether the CD38-/low post-switch memory B cells
in the peripheral blood of patients with RA are similar
to the cells described in the synovial tissue cannot be
answered yet. Since the latter cells are enriched in the
peripheral blood, it is now possible to perform
functional assays and determine whether CD38- B cells
are similar to mouse B cells that lack RelB and that are
defective in proliferative responses but are able to
secrete immunoglobulins and undergo class switching
[23].
Recently, treatment with tumor necrosis factor (TNF)
blockers was shown to alter the distribution of peripheral
blood B cells [24]. Thus, infliximab therapy induces an
increase in pre-switch memory B cells. Although the
majority of our patients have received TNF inhibitors in
the past, we did not find this difference. In contrast, our
patients exhibited similarly low median percentages of
IgD+CD27+ memory B cells (8.6% and 6.8% for respon-
ders and non-responders, respectively) as described for
patients with long-standing RA (10.4%). In addition, the
frequencies of these B-cell subsets in the control groups
in this study and in the article by Souto-Carneiro and
Figure 4 Model of B-cell differentiation (adapted from [10,12,16]). *All patients with rheumatoid arthritis (RA) had significantly fewer CD38+
post-switch B cells in comparison with healthy age-matched controls. European League Against Rheumatism (EULAR) non-responders (NR) had a
significantly higher frequency of CD95+ pre-switch memory B cells. Rituximab responders (R) had significantly lower levels of plasmablast before
treatment and more B cells differentiated into double-negative B cells that are less likely to generate plasma cells [29].
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colleagues [24] were almost identical (14.9% and 15.1%,
respectively). It is fascinating to speculate whether the
missing increase in pre-switch memory B cells is a surro-
gate marker for TNF failure, but further studies have to
confirm these results.
Although pre-switch memory B cells are reduced in our
RA cohort, this subset is significantly enriched in CD95+
cells in non-responders (Figure 3e). Similar results were
found in patients with SLE [25]. It has been suggested
that, in SLE, the pre-switch B-cell population is enriched
in autoantibody-producing B cells that are constantly
recruited into lymphoid tissue and that therefore are
found less often in the peripheral blood. Under physiologi-
cal conditions, expression of CD95 is important in main-
taining peripheral self-tolerance by inducing apoptosis
upon engagement with its ligand, CD178 [26]. In RA,
defects of this pathway have been demonstrated [27], and
accumulation of autoantibody-secreting plasma cells in
synovium has been suggested to be the result of the lack
of this regulatory mechanism [28]. Our results suggest
that an increased frequency of activated (that is, CD95+
pre-switch memory) B cells is associated with poor
response to rituximab. Figure 4 summarizes the alterations
in the different B-cell subsets between EULAR responders
and non-responders compared with healthy age-matched
controls. Despite the great efforts made, neither certain
cell populations nor serum markers that might help to
choose a specific therapy have been found so far. The het-
erogeneity of the patients with RA (for example, disease
duration, previous medication, or co-medication or a com-
bination of these) could skew the results.
Conclusions
In summary, even in this small cohort, the frequency of
plasmablast seems to be the best predictor for response
to a B cell-depleting therapy. Still, prospective studies
have to confirm this finding. High-sensitivity flow cyto-
metry appears to be very helpful to narrow further
candidates.
Additional material
Additional file 1: Figure S1 Gating strategy. Mononuclear cells were
incubated in 4 separate tubes containing the following monoclonal
antibodies: a) Isotypen-specific control antibodies; b) IgD-FITC, CD27-APC,
CD38-PE/Cy7, CD45-APC/H7, CD19-HorizonBlue, CD24-PE, CD3-/CD14-
PerCP; c) IgD-FITC, CD27-APC, CD38-PE/Cy7, CD45-APC/H7, CD19-
HorizonBlue, CD80-PE, CD3-/CD14-PerCP; d) IgD-FITC, CD27-APC, CD38-
PE/Cy7, CD45-APC/H7, CD19-HorizonBlue, CD95-PE, CD3-/CD14-PerCP.
CD45 positive leukocytes were gated and after eliminating PerCP positive
T cells and monocytes, B cells were separated according to their CD27
and IgD expression. Thereafter the expression of CD38, CD80 or CD95
was analyzed in each B cell population.
Additional file 2: Figure S2 Effect of the time of preparation on the
number of day 15 B cells in RA patients with good/moderate or no
EULAR response.
Additional file 3: Figure S3 Frequency of CD95+ cells in the naïve,
post-switch and double negative B cell subset.
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